FPF
SVA

FNY Partners Fund’s Sinovac Biotech, Ltd SVA Stock Holding History

FNY Partners Fund’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,000
Closed -$33K – 820
2017
Q2 		$33K Sell
5,000
-9,064
-64% -$49.7K 0.01% 305
2017
Q1 		$80K Buy
+14,064
New +$81.4K 0.01% 584

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FNY Partners Fund's SVA Position: Q3 2017 in Review

FNY Partners Fund sold out of Sinovac Biotech, Ltd (SVA) in Q3 2017, closing a stake of 5,000 shares — an estimated $33K sold.

FNY Partners Fund first reported a position in SVA in Q1 2017 and held it in 2 quarters. The position peaked at $80K in Q1 2017. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2017.

  • FNY Partners Fund reported no remaining Sinovac Biotech, Ltd position as of Q3 2017 after selling out during the quarter.
  • FNY Partners Fund sold 5,000 Sinovac Biotech, Ltd shares in Q3 2017, an estimated $33K.
  • FNY Partners Fund first reported a position in Sinovac Biotech, Ltd in Q1 2017 and held it in 2 quarters.
  • FNY Partners Fund's Sinovac Biotech, Ltd position peaked at $80K in Q1 2017.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.